Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245507 | 0.89 | CES2 (0.55) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL1198300 | 0.86 | CES2 (0.53) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL16396412 | 0.85 | RAB9A (0.63) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL7785000 | 0.82 | CES2 (0.62) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL1199274 | 0.81 | LMNA (0.47) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL11524668 | 0.81 | MAPT (0.59) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL27530365 | 0.80 | RAB9A (0.57) | CES2CES1TP53ALDH1A1MEN1 | |
| SCHEMBL181572 | 0.79 | CES2 (0.78) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL8623532 | 0.78 | ALDH1A1 (0.58) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL8962468 | 0.78 | CES2 (0.75) | CES2CES1TP53ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282991-B1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-8461312-B2 | Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-8461312-B2 | Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2009132832-A2 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | BBOX1, SULT1E1, PTGS1 | CES2 1116/4885CES1 205/4885TP53 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.